Skip to content
  • News
  • Compare
  • Capital
variis
  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Events
  • Funds
  • Press
variis

Longevity intelligence for Singapore and Australia. Sourced and evidence-graded.

Directories

  • Clinics
  • Companies
  • Protocols
  • Specialists
  • Funds
  • Events

Read

  • Archive
  • Capital
  • Compare
  • Glossary

Markets

  • Singapore
  • Australia

variis

  • About
  • Editorial standards
  • AI transparency
  • Corrections
  • Press

Legal

  • Medical disclaimer
  • Privacy policy
  • Terms of service

AI-assisted reporting, human-reviewed. Every claim sourced and graded. Not medical advice.

© 2026 variis · Singapore · Australia

  1. Home
  2. Companies
  3. Immutep Limited

Company

Immutep Limited

ASX:IMM

Immutep develops immunotherapies built around LAG-3, an immune checkpoint protein that regulates T-cell activity. Its portfolio runs in two directions from the same biology: agonist-style candidates (led by eftilagimod alfa, a soluble LAG-3 protein) intended to stimulate antigen-presenting cells and T-cells against tumours, and antagonist candidates intended to damp down T-cell activity in autoimmune disease. That two-sided position on T-cell regulation is what makes it relevant to the immune-ageing (immunosenescence) axis rather than to a single tumour type. It is not a geroscience company and does not run ageing-endpoint trials; the longevity link is mechanistic, via immune regulation, not by stated intent. Inclusion is on both limbs of the rule: ASX-listed and Sydney-headquartered. The honest negative: its most advanced oncology programme failed a Phase III interim futility analysis in March 2026, so the near-term clinical case rests on the remaining earlier-stage assets.

At a glance

Listing
ASX:IMM
Category
ASX listed
Headquarters
Sydney, New South Wales, Australia
Market cap
Not disclosed

Thesis

Why it is in this universe

Category
ASX listed
Market
Australia
Recent inflection
13 March 2026: the Independent Data Monitoring Committee recommended discontinuing the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer following a planned interim futility analysis. Enrolment was halted and the study wound down. The company said its cash runway would extend well beyond the previously guided Q2 CY2027, without giving a revised figure at the time. Immutep's Nasdaq ADRs fell from US$2.76 to US$0.48 on the announcement, about 83 percent. Source: GlobeNewswire company release, 13 March 2026.
Services
None recorded
People tracked
None on file

Market data

Listing and scale

MetricDetail
ExchangeASX
TickerASX:IMM
Secondary listingNASDAQ
Market capNot disclosed
StatusListed and trading
Editor's noteA listing or financing event is not a clinical result. variis grades evidence on the linked protocol, not the share price.

Get in touch

Contact

Address
Sydney, New South Wales, Australia
Website
www.immutep.com
Phone
No public number published
Email
No public address published

Offering

What it sells today

No commercial services are recorded for this company yet.

Recent inflection

What moved lately

13 March 2026: the Independent Data Monitoring Committee recommended discontinuing the Phase III TACTI-004 trial of eftilagimod alfa in first-line non-small cell lung cancer following a planned interim futility analysis. Enrolment was halted and the study wound down. The company said its cash runway would extend well beyond the previously guided Q2 CY2027, without giving a revised figure at the time. Immutep's Nasdaq ADRs fell from US$2.76 to US$0.48 on the announcement, about 83 percent. Source: GlobeNewswire company release, 13 March 2026.

Common questions

Why does variis track Immutep Limited?
Immutep develops immunotherapies built around LAG-3, an immune checkpoint protein that regulates T-cell activity. Its portfolio runs in two directions from the same biology: agonist-style candidates (led by eftilagimod alfa, a soluble LAG-3 protein) intended to stimulate antigen-presenting cells and T-cells against tumours, and antagonist candidates intended to damp down T-cell activity in autoimmune disease. That two-sided position on T-cell regulation is what makes it relevant to the immune-ageing (immunosenescence) axis rather than to a single tumour type. It is not a geroscience company and does not run ageing-endpoint trials; the longevity link is mechanistic, via immune regulation, not by stated intent. Inclusion is on both limbs of the rule: ASX-listed and Sydney-headquartered. The honest negative: its most advanced oncology programme failed a Phase III interim futility analysis in March 2026, so the near-term clinical case rests on the remaining earlier-stage assets.
Is Immutep Limited publicly listed?
Yes. It trades as ASX:ASX:IMM. variis records the listing, not a live price.
Where is Immutep Limited based?
Sydney, New South Wales, Australia
Is Immutep Limited still trading?
Immutep Limited is recorded as actively trading.

Keep reading

Related coverage from the newsroom.

Singapore and Australia · Capital

Singapore and Australia · Capital

Two rounds, one IPO: how Singapore and Australia are funding longevity in 2025 to 2026

Suggest an update

Sources

What this profile is built on

  1. Immutep: LAG-3 immunotherapy, four clinical-stage assets in oncology and autoimmune disease; HQ Level 32, Australia Square, 264 George Street, Sydney NSW 2000 · Immutep Limited
  2. TACTI-004 Phase III Study in First Line NSCLC to be discontinued following Futility Analysis · GlobeNewswire (Immutep Limited release, 13 March 2026)
  3. Immutep hit with securities suit after TACTI-004 trial halt and 83% stock drop · TipRanks

Last updated 14 August 2026

Every entity profile on variis is sourced. Not investment advice.